News

Zacks Investment Research on MSN3h
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...
Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will
Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...
Health and Me on MSN1d
This Weight Loss Injection Can Now Treat Sleep Apnea; Are There Any Side Effects?
Mounjaro (tirzepatide), a weight-loss injection, is now approved to treat moderate-to-severe obstructive sleep apnea in obese ...
Should You Invest $1,000 in Eli Lilly today?
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...
Experts Just Discovered The Most Effective New Weight Loss Drug—And It's Not Ozempic
New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug
Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.
New Research Reveals Most Effective Obesity Drug: It’s Not Ozempic or Wegovy
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...